Biolexis Private Limited
About Biolexis Private Limited
Data last updated:
Biolexis Private Limited is a private limited company based in Bangalore, Karnataka, India. It operates in the drug formulation and development segment of the pharmaceuticals sector. It was incorporated on 17 January 2022.
The company is registered with the Registrar of Companies (ROC), Bangalore, under CIN U24239KA2022PTC156696.
The company has an authorised share capital of ₹50 Cr and a paid-up capital of ₹38.75 Cr. It is led by directors including Chirag Dalal (Whole-Time Director) and Chunky Agarwal.
Its last annual general meeting (AGM) was held on 19 September 2025, and its latest financial statements are for the year ended 31 March 2025. The registered office is at Star 1, Opp Iim Bangalore Bilekahalli, Karnataka, India – 560076.
As per the financials filed for FY 2025, the company reported a revenue of ₹1.87 Cr. For the same year it recorded a net profit of ₹1.09 Cr (net margin 58.4%) and EBITDA of ₹1.26 Cr (EBITDA margin 67.6%).
The current compliance status is marked as compliant by the Registrar of Companies.
- EmailLocked
- TelephoneLocked
- WebsiteLocked
- Social MediaLocked
- Registered AddressStar 1, Opp Iim Bangalore Bilekahalli, Karnataka, India – 560076
- IndustryPharma, Drug Formulation & Development
- Company details, directors and signatories
- Historical financials and ratios
- Shareholding pattern and group structure
- Charges with holder and property details
- Legal cases, compliance and MCA filings
- One PDF report, delivered after checkout
Financials of Biolexis Private Limited FY 2025 filings available
Biolexis Private Limited reported revenue of ₹1.87 Cr for FY 2025.
Financial Statement Summary of Biolexis Private Limited
| Metrics | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 |
|---|---|---|---|---|
| Profit and Loss Statement | ||||
| Revenue from Operations | •••• | •••• | •••• | •••• |
| Other Income | •••• | •••• | •••• | •••• |
| Total Revenue | •••• | •••• | •••• | •••• |
| Cost of Materials Consumed | •••• | •••• | •••• | •••• |
| Employee Benefit Expense | •••• | •••• | •••• | •••• |
| Finance Costs | •••• | •••• | •••• | •••• |
| Depreciation and Amortisation | •••• | •••• | •••• | •••• |
| Other Expenses | •••• | •••• | •••• | •••• |
| Total Expenses | •••• | •••• | •••• | •••• |
| EBITDA | ₹1.26 Cr | •••• | •••• | •••• |
| Profit Before Tax | •••• | •••• | •••• | •••• |
| Tax Expense | •••• | •••• | •••• | •••• |
| Net Profit (PAT) | ₹1.09 Cr | •••• | •••• | •••• |
| Balance Sheet | ||||
| Share Capital | •••• | •••• | •••• | •••• |
| Reserves and Surplus | •••• | •••• | •••• | •••• |
| Net Worth (Total Equity) | •••• | •••• | •••• | •••• |
| Long-term Borrowings | •••• | •••• | •••• | •••• |
| Short-term Borrowings | •••• | •••• | •••• | •••• |
| Trade Payables | •••• | •••• | •••• | •••• |
| Total Liabilities | •••• | •••• | •••• | •••• |
| Fixed Assets | •••• | •••• | •••• | •••• |
| Investments | •••• | •••• | •••• | •••• |
| Inventories | •••• | •••• | •••• | •••• |
| Trade Receivables | •••• | •••• | •••• | •••• |
| Cash and Bank Balance | •••• | •••• | •••• | •••• |
| Total Assets | •••• | •••• | •••• | •••• |
Financial Ratios of Biolexis Private Limited
| Metrics | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 |
|---|---|---|---|---|
| Profitability | ||||
| EBITDA Margin | 67.6% | •••• | •••• | •••• |
| Net Profit Margin | 58.4% | •••• | •••• | •••• |
| Return on Equity (ROE) | •••• | •••• | •••• | •••• |
| Return on Capital Employed (ROCE) | •••• | •••• | •••• | •••• |
| Return on Assets (ROA) | •••• | •••• | •••• | •••• |
| Liquidity and Debt | ||||
| Current Ratio | •••• | •••• | •••• | •••• |
| Quick Ratio | •••• | •••• | •••• | •••• |
| Debt-to-Equity Ratio | •••• | •••• | •••• | •••• |
| Interest Coverage Ratio | •••• | •••• | •••• | •••• |
| Efficiency and Growth | ||||
| Asset Turnover | •••• | •••• | •••• | •••• |
| Receivable Days | •••• | •••• | •••• | •••• |
| Payable Days | •••• | •••• | •••• | •••• |
| Inventory Days | •••• | •••• | •••• | •••• |
| Revenue Growth | •••• | •••• | •••• | •••• |
| Net Profit Growth | •••• | •••• | •••• | •••• |
Paid data: the figures shown as dots are available after purchase of the company report. Figures as filed with the MCA in Form AOC-4. The full year-wise statements and ratios of Biolexis are in the company report.
Financial statements from FY 2022
Earlier years and trend charts are in the company report.
- Income statements
- Balance sheets
- Cash-flow statements
- Ratios and benchmarks
Verified entity values are shown only after access is granted.
Peer Comparison of Biolexis Private Limited
Biolexis Private Limited is compared with the companies closest to it by revenue in the Pharma industry (Formulations). Net profit, margin and employee counts of each company are in the company report.
| Company | Revenue | Net profit | Margin | Growth (1 yr) | Employees | Location |
|---|---|---|---|---|---|---|
| Kosmocare Lifesciences Private Limited | ₹1.88 Cr (FY 2025) | •••• | •••• | 452.0% | •••• | New Delhi, Delhi, India |
| Aaditri TPS Private Limited | ₹1.88 Cr (FY 2025) | •••• | •••• | -9.0% | •••• | Patna, Bihar, India |
| Hublore Healthcare Private Limited | ₹1.87 Cr (FY 2024) | •••• | •••• | 30.0% | •••• | Ahmedabad, Gujarat, India |
| Xsense Lifesciences Private Limited | ₹1.87 Cr (FY 2025) | •••• | •••• | 96.0% | •••• | Ahmedabad, Gujarat, India |
| Frankfurt Pharmaceuticals Private Limited | ₹1.87 Cr (FY 2025) | •••• | •••• | 10.0% | •••• | New Delhi, Delhi, India |
| Biolexis Private Limited this company | ₹1.87 Cr (FY 2025) | •••• | •••• | •••• | Bangalore, Karnataka, India | |
| Nexa Healthcare Private Limited | ₹1.87 Cr (FY 2024) | •••• | •••• | 3.0% | •••• | Meerut, Uttar Pradesh, India |
| Booty Pharma Private Limited | ₹1.87 Cr (FY 2024) | •••• | •••• | -25.0% | •••• | Uttar Pradesh, India |
| Ubix Bioscience Private Limited | ₹1.86 Cr (FY 2024) | •••• | •••• | 24.0% | •••• | Uttarakhand, India |
| Heal Sure Lifesciences Private Limited | ₹1.86 Cr (FY 2025) | •••• | •••• | -3.0% | •••• | Ahmedabad, Gujarat, India |
| Leewell Pharmaceuticals Private Limited | ₹1.86 Cr (FY 2025) | •••• | •••• | 94.0% | •••• | Hyderabad, Telangana, India |
Peers are the five companies nearest above and the five nearest below Biolexis by revenue in the Pharma industry (Formulations), from the latest filed financials of each company. Net profit, margin and employee counts of each peer are in the company report.
Board of Directors of Biolexis Private Limited
Biolexis has 3 current directors and 7 former directors. Current directors are listed first, with their designation and appointment date.
| Name | Designation | Appointment Date | Tenure | Status |
|---|---|---|---|---|
| Chunky Agarwal | Director | 12 Jun 2024 | 2 Years 3 Months | Current |
| Allada Trisha | Director | 25 Jul 2024 | 2 Years 2 Months | Current |
| Chirag Dalal Also directs: Strides Pharma Services Private Limited | Whole-Time Director | 13 Nov 2025 | 0 Years 10 Months | Current |
Charges & Borrowings of Biolexis Private Limited
Biolexis Private Limited does not have any charges (loans) registered with the Registrar of Companies.
Employees and EPFO Compliance at Biolexis Private Limited
Employment history and EPFO contributions of people linked to Biolexis.
Employee and EPFO history
Monthly headcount, contribution history and filing status are in the company report.
- Monthly headcount
- PF contributions
- ECR filing status
- Establishment history
Verified entity values are shown only after access is granted.
Recent Activity on Biolexis Private Limited
Biolexis Private Limited has 9 board changes on record since 2023: 4 appointments and 5 cessations. The latest: Chirag Dalal was appointed as Whole-Time Director on 13 Nov 2025.
Credit Ratings, Litigation & Regulatory Alerts for Biolexis Private Limited
Credit ratings, litigation, and regulatory alerts
Credit ratings, court records and regulatory alerts are in the company report.
- Rating history
- Court and tribunal cases
- Regulatory alerts
- Director-linked violations
Verified entity values are shown only after access is granted.
MSME Payment Delays by Biolexis Private Limited
MSME payment history
Amounts due to small suppliers, the reasons given and MSME-1 filings are in the company report.
- Outstanding amounts
- Delay periods and reasons
- MSME-1 filing history
- Vendor payment signals
Verified entity values are shown only after access is granted.
Subsidiaries & Group Companies of Biolexis Private Limited
Corporate group structure
Parent, subsidiary, associate and joint venture records with holdings are in the company report.
- Parent company
- Subsidiaries and ownership
- Associates and joint ventures
- Entity investments
Verified entity values are shown only after access is granted.
GST Compliance of Biolexis Private Limited
GST registrations and filing compliance
State-wise GST registrations, return filing status and HSN or SAC codes are in the company report.
- GSTIN registrations
- State-wise filing status
- HSN and SAC details
- Tax jurisdiction records
Verified entity values are shown only after access is granted.
MCA Filings & Documents of Biolexis Private Limited
MCA filings and documents
Filed forms, annual returns, financial statements and charge filings with their dates are in the company report.
- Incorporation documents
- Annual returns and statements
- Charge filings
- Complete filing index
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Biolexis Private Limited
Biolexis is an active private limited company based in Bangalore, Karnataka, India. The company works in drug formulation and development, within the pharma industry. It was incorporated on 17 January 2022 (4+ years old) and is registered under CIN U24239KA2022PTC156696.
Biolexis reported revenue of ₹1.87 Cr for FY 2025.
Biolexis has 3 current directors:
- Chirag Dalal - Whole-Time Director
- Chunky Agarwal - Director
- Allada Trisha - Director
Biolexis reported a net profit of ₹1.09 Cr (net margin 58.4%) and EBITDA of ₹1.26 Cr (EBITDA margin 67.6%) for FY 2025, as per its filed financial statements.
The CIN (Corporate Identification Number) of Biolexis is U24239KA2022PTC156696. It is issued by the Ministry of Corporate Affairs under the Companies Act, 2013, and uniquely identifies the company in India.
Biolexis was incorporated on 17 January 2022, making it 4+ years old. It is registered with the Registrar of Companies, Bangalore.
The peers of Biolexis by revenue are Kosmocare Lifesciences Private Limited, Aaditri TPS Private Limited, Hublore Healthcare Private Limited, Xsense Lifesciences Private Limited, Frankfurt Pharmaceuticals Private Limited and 5 more, all in the Pharma industry (Formulations).
Chirag Dalal was appointed as Whole-Time Director on 13 Nov 2025. Naveen . Madan was appointed as CFO on 02 May 2025. Allada Trisha ceased to be Additional Director on 20 Aug 2024. Biolexis has 9 board changes on record in total.
The registered office of Biolexis is at Star 1, Opp Iim Bangalore Bilekahalli, Karnataka, India – 560076.
Biolexis has an authorised share capital of ₹50 Cr and a paid-up capital of ₹38.75 Cr.
Biolexis operates in the pharma industry, in the drug formulation and development segment.